预约演示
更新于：2026-01-31
Ertapenem Sodium
厄他培南钠
更新于：2026-01-31
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-11-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H25N3NaO7S |
InChIKeyOBWHPSQEAHSXMM-HRXMHBOMSA-N |
CAS号153773-82-1 |
关联
85
项与 厄他培南钠 相关的临床试验CTIS2024-516232-10-00
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
CTIS2024-515958-24-00
Preoperative Antibiotics for Mild or Moderate Acute Cholecystitis (POMMAC): A Non-inferiority, Open-label, Randomized Controlled Trial – Study Protocol
NCT06920147
PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network
100 项与 厄他培南钠 相关的临床结果
登录后查看更多信息
100 项与 厄他培南钠 相关的转化医学
登录后查看更多信息
100 项与 厄他培南钠 相关的专利（医药）
登录后查看更多信息
6,828
项与 厄他培南钠 相关的文献（医药）2026-06-01Biofilm
Staphylococcal persistence and biofilm resistance in bone-anchored hearing systems: Clinical impact
Article
作者: Hoffman, Maria ; Hultcrantz, Malou ; Ganeyev, Marsel ; Trobos, Margarita ; Thomsen, Peter ; Johansson, Martin L ; Palmquist, Anders ; Morales-Laverde, Liliana
Persistent inflammation and infection, often linked to staphylococcal colonization, affect bone-anchored hearing system (BAHS) outcomes. Although antibiotics are often used to treat skin complications, the roles of biofilms and antimicrobial resistance (AMR) in clinical success remain unclear. This clinical prospective study characterized biofilm formation and antibiotic resistance in Staphylococcus spp. from BAHS patients, and examined associations with inflammation, pain, and hygiene. Adults eligible for BAHS were prospectively enrolled at a tertiary university hospital in Sweden during 2014-2015. Fifteen patients were followed clinically and microbiologically at surgery, 3- and 12- months. Abutment, peri-abutment exudate and soft-tissue samples were cultured. Fifty-seven Staphylococcus spp. isolates underwent biofilm phenotyping (Crystal Violet, Congo Red), antimicrobial susceptibility testing (minimum inhibitory concentration [MIC], minimum biofilm eradication concentration [MBEC]) and whole-genome sequencing (lineage, AMR and virulence genes). Clinical status was scored (Holgers, pain, debris). Individual patients harbored the same staphylococcal clone on abutment, exudate, and tissue for 12 months. S. aureus was more prevalent in patients with inflammation (Holgers score >0), S. epidermidis correlated with pain, and slime production was associated with debris accumulation. Overall, 56 % of isolates showed resistance to fusidic acid, and 11-34 % carried tetracycline resistance genes. S. epidermidis carried multidrug resistance genes (beta-lactams, tetracycline, sulfamethoxazole, fosfomycin), and resistance increased under biofilm conditions (MBEC > MIC). The ica operon was detected in all S. aureus and S. epidermidis ST7, ST297, ST749 and ST278. These findings indicate that staphylococci from BAHS exhibit persistent colonization, diverse clonal lineages, and high biofilm-associated AMR. Early microbial diagnostics and biofilm-targeted strategies, alongside cautious use of topical antibiotics, may improve outcomes.
2026-03-01RESEARCH IN VETERINARY SCIENCE
Antimicrobial resistance and virulence-associated genes in Escherichia coli from young healthy chickens
Article
作者: Di Paolo, Alessia ; Bertelloni, Fabrizio ; Timofte, Dorina ; Zendri, Flavia ; Cagnoli, Giulia ; Ebani, Valentina Virginia ; Marzoni Fecia di Cossato, Margherita
Escherichia coli is a commensal intestinal bacterium of humans and animals and is frequently associated with antimicrobial resistance (AMR). This study investigated the phenotypic and genotypic AMR and virulence factors in E. coli isolated from 120 young healthy chickens never treated with antibiotics and coccidiostats. The disk diffusion method employed on all 120 isolates revealed the highest resistance (11.67%) to chloramphenicol and trimethoprim-sulfamethoxazole. All isolates were susceptible to aztreonam and gentamicin, whereas over 95% showed susceptibility to amikacin, cefoxitin, ciprofloxacin, and ertapenem. Minimum inhibition concentration test found 7 (5.83%) isolates resistant to colistin. Eight strains (6.67%) were found to be multidrug-resistant (MDR). Molecular analyses conducted on resistant and intermediate isolates showed that 11/13 penicillin-resistant strains carried the blaTEM gene, 12/12 tetracycline-resistant strains had tetA, 4/14 chloramphenicol-resistant and 1/2 chloramphenicol-intermediate strains had cmlA. The astA gene, potentially indicative of enteroaggregative E. coli (EAEC), was found in 15% of isolates. Virulence genes characterizing other pathotypes investigated were not detected. Chickens reared in optimal conditions and never treated with antibiotics may harbor antimicrobial-resistant and pathogenic bacterial strains that could become a public health hazard. Good farm management and hygiene are fundamental to reducing the circulation of pathogenic strains and the need for antimicrobial treatments.
2026-02-01JOURNAL OF CRITICAL CARE
Continuous infusion of Beta-Lactams in the critically ill: Considerations for global implementation
Review
作者: Rajbhandari, Dorrilyn ; Mehta, Reena ; Lipman, Jeffery ; Best-Lane, Janis ; Brett, Stephen J ; Mangalore, Rekha Pai ; Denny, Kerina J ; Scribante, Juan ; Dulhunty, Joel ; Gous, Andries G S ; Machado, Flavia R
β-lactam antibiotics are the most commonly used antibiotics for the empiric and targeted treatment of infection in the critically ill. Timely administration of an effective dose of β-lactams is critical to reduce infection-associated morbidity and mortality. Continuous infusion (CI) of β-lactam antibiotics is now an evidence-based strategy to optimise treatment in critically ill patients with infection. However, the widespread implementation of CI of β-lactams requires consideration of various practical and pharmaceutical related factors. The following addresses barriers to the implementation of CI of β-lactam antibiotics, including specific considerations for low resource settings, and aims to provide practical solutions for the translation of evidence into practice.
100 项与 厄他培南钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 菌血症 | 中国 | 2005-09-12 | |
| 细菌感染 | 中国 | 2005-09-12 | |
| 复杂的皮肤和软组织感染 | 中国 | 2005-09-12 | |
| 肾盂肾炎 | 中国 | 2005-09-12 | |
| 泌尿道感染 | 中国 | 2005-09-12 | |
| 感染性流产 | 澳大利亚 | 2002-06-11 | |
| 子宫内膜炎 | 澳大利亚 | 2002-06-11 | |
| 糖尿病足感染 | 欧盟 | 2002-04-18 | |
| 糖尿病足感染 | 冰岛 | 2002-04-18 | |
| 糖尿病足感染 | 列支敦士登 | 2002-04-18 | |
| 糖尿病足感染 | 挪威 | 2002-04-18 | |
| 妇科感染 | 欧盟 | 2002-04-18 | |
| 妇科感染 | 冰岛 | 2002-04-18 | |
| 妇科感染 | 列支敦士登 | 2002-04-18 | |
| 妇科感染 | 挪威 | 2002-04-18 | |
| 腹腔感染 | 欧盟 | 2002-04-18 | |
| 腹腔感染 | 冰岛 | 2002-04-18 | |
| 腹腔感染 | 列支敦士登 | 2002-04-18 | |
| 腹腔感染 | 挪威 | 2002-04-18 | |
| 手术伤口感染 | 欧盟 | 2002-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺炎 | 临床3期 | - | 2005-07-01 | |
| 脓毒症 | 临床3期 | - | 2004-09-01 | |
| 医院获得性肺炎 | 临床2期 | - | 2002-03-01 | |
| 细菌性肺炎 | 临床2期 | - | 2002-01-01 | |
| 传染性皮肤病 | 临床2期 | - | 2002-01-01 | |
| 软组织感染 | 临床2期 | - | 2002-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 343 | 齋廠選鹽餘餘獵鏇衊範(鏇艱鏇鏇壓願遞選醖夢) = 獵選壓顧鹽餘醖築鹹衊 簾簾觸鬱製襯餘艱夢壓 (蓋鑰繭壓簾觸壓簾艱醖 ) | 不佳 | 2026-01-16 | |||
齋廠選鹽餘餘獵鏇衊範(鏇艱鏇鏇壓願遞選醖夢) = 醖淵觸廠簾獵淵廠獵繭 簾簾觸鬱製襯餘艱夢壓 (蓋鑰繭壓簾觸壓簾艱醖 ) | |||||||
临床1期 | 54 | (Cohort 1 - WCK 6777 2 g) | 蓋顧遞憲鏇淵鹹糧醖顧 = 襯憲鬱鹽觸齋艱簾顧壓 顧觸觸鏇襯網網鑰鏇範 (範遞積廠選壓壓鑰糧鬱, 製鑰糧蓋壓窪艱繭積襯 ~ 廠顧鏇艱衊壓壓廠鑰獵) 更多 | - | 2024-12-05 | ||
ERT (Cohort 2 - ERT 2 g) | 蓋顧遞憲鏇淵鹹糧醖顧 = 醖鏇膚鏇獵餘窪製廠夢 顧觸觸鏇襯網網鑰鏇範 (範遞積廠選壓壓鑰糧鬱, 觸淵遞構築簾製選淵選 ~ 淵築簾願糧鏇範鏇製選) 更多 | ||||||
N/A | 1,032 | 觸獵壓選壓鏇憲鹽醖鹽(獵鹹衊鹹壓糧願壓憲築) = 選糧膚壓積齋願構積蓋 衊夢繭鏇範顧醖網衊積 (繭構遞築觸餘鬱繭餘積 ) | - | 2023-05-30 | |||
Class 2 carbapenems | 觸獵壓選壓鏇憲鹽醖鹽(獵鹹衊鹹壓糧願壓憲築) = 衊夢鑰遞齋遞獵鹽壓窪 衊夢繭鏇範顧醖網衊積 (繭構遞築觸餘鬱繭餘積 ) | ||||||
N/A | 1,552 | (Antibiotics Therapy Arm) | 艱醖築蓋壓選艱鏇鑰憲(鑰廠積網艱簾構鹹築顧) = 憲夢窪遞夢衊遞遞餘繭 餘構網衊繭網簾餘顧繭 (窪獵簾窪餘鹹餘鹽鬱願, 0.13) 更多 | - | 2023-04-18 | ||
Appendectomy (Appendectomy Arm) | 艱醖築蓋壓選艱鏇鑰憲(鑰廠積網艱簾構鹹築顧) = 網簾夢顧積鬱艱淵築選 餘構網衊繭網簾餘顧繭 (窪獵簾窪餘鹹餘鹽鬱願, 0.13) 更多 | ||||||
临床4期 | - | 26 | (Intravenous (IV) administration) | 廠鏇廠鹹窪鬱醖膚網衊(艱鹽顧繭壓築廠獵鬱淵) = 廠窪獵鹽構簾鏇願顧淵 衊憲艱網顧憲鏇憲夢觸 (鏇鹹醖選顧蓋網範鏇壓 ) 更多 | - | 2019-12-01 | |
(Subcutaneous (SC) administration) | 廠鏇廠鹹窪鬱醖膚網衊(艱鹽顧繭壓築廠獵鬱淵) = 艱顧網鏇廠選構獵窪獵 衊憲艱網顧憲鏇憲夢觸 (鏇鹹醖選顧蓋網範鏇壓 ) 更多 | ||||||
临床2期 | 7 | 製鬱壓願顧憲衊繭選醖(醖構糧淵襯憲廠遞製鹽) = 襯製鏇糧鏇觸衊餘鏇顧 鹹糧夢築餘網餘觸顧壓 (網艱鑰製繭餘獵選餘壓, 904.9) 更多 | - | 2017-06-15 | |||
临床4期 | - | De-escalation group (ertapenem) | 糧壓窪蓋糧製憲觸顧鑰(鬱鹹醖選構獵積蓋襯顧) = 窪製鹽憲鏇積餘襯顧艱 選構壓觸襯製廠製鑰繭 (鬱鹽網構襯積遞憲製艱 ) 更多 | 积极 | 2017-03-01 | ||
Control group (group 2 carbapenem) | 糧壓窪蓋糧製憲觸顧鑰(鬱鹹醖選構獵積蓋襯顧) = 獵鏇觸簾築願選糧積獵 選構壓觸襯製廠製鑰繭 (鬱鹽網構襯積遞憲製艱 ) 更多 | ||||||
临床4期 | 23 | 蓋膚襯憲蓋構鏇壓醖餘(鏇構願鏇網膚鏇願憲選) = 膚顧積觸網糧構願網簾 廠鏇顧鏇網鹹鬱餘顧鏇 (夢夢壓衊構齋齋窪鏇觸, 2.3) 更多 | - | 2016-12-16 | |||
临床3期 | 565 | 選鏇膚窪膚積糧蓋繭糧(鏇淵艱鬱襯顧蓋齋齋衊) = 網糧網簾繭網範繭糧壓 鏇廠構鏇築鏇糧積鬱鹹 (夢廠製蓋鑰製餘壓鏇膚 ) 更多 | 非劣 | 2016-06-01 | |||
piperacillin/tazobactam | 選鏇膚窪膚積糧蓋繭糧(鏇淵艱鬱襯顧蓋齋齋衊) = 糧壓積襯夢糧醖襯獵範 鏇廠構鏇築鏇糧積鬱鹹 (夢廠製蓋鑰製餘壓鏇膚 ) 更多 | ||||||
临床3期 | 565 | (Ertapenem Sodium) | 簾構憲鹹窪艱鏇鑰鬱遞 = 積繭窪築窪選獵築壓選 鑰網蓋鏇獵衊鬱選網鹹 (艱簾窪鏇構選鏇鏇構築, 醖製構餘獵壓衊襯鏇衊 ~ 齋鹽齋襯鹹選憲膚齋範) 更多 | - | 2014-12-02 | ||
(Piperacillin/Tazobactam Sodium) | 簾構憲鹹窪艱鏇鑰鬱遞 = 鏇糧積鹹簾積鑰顧鑰憲 鑰網蓋鏇獵衊鬱選網鹹 (艱簾窪鏇構選鏇鏇構築, 衊窪膚構遞糧繭鏇願繭 ~ 鹽膚獵顧觸積範衊鹹範) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用